Recruiting for Challenging Indications
Our knowledge of clinical trials and expertise in specific indications means that we have proven solutions to recruitment in more challenging indications.
Innovative Alzheimer’s disease registry to increase pool of available patients
Onsite FibroScan® screening capabilities to help enroll NASH patients
Specialized techniques to target IBD patients
Mild cognitive impairment and Alzheimer’s disease
Mild cognitive impairment (MCI) and Alzheimer’s disease can be particularly challenging to recruit. Physicians are often reluctant to refer asymptomatic or mildly impaired patients to clinical trials because they believe investigational drugs may offer no better benefit than previous failed Alzheimer’s disease drugs. Yet the greatest benefit of treatment is often observed in those in the very early stages of cognitive decline.
AES has been innovative in solving this challenge. We’ve partnered with academia to set up the Synexus HealthyMinds Registry. This five-year study assesses and monitors participants, enabling cognitive testing at scale. It’s improved knowledge of the condition by identifying the factors impacting cognitive decline. It also facilitates recruitment of prodromal patients for Alzheimer’s disease trials from this specific patient population. Our patient database, the largest globally, also contains more than one million households with cognitive decline due to Alzheimer’s disease or other forms of dementia.